Literature DB >> 22198693

Optic neuritis after infliximab therapy.

César Faillace, João Ricardo Maltez de Almeida, Jozélio Freire de Carvalho.   

Abstract

Demyelinating diseases were described in patients receiving anti-TNF agents. Optic neuritis (ON) induced by TNF blockers was already described in 22 cases in the literature. In this article, the authors report a 53-year-old woman with refractory rheumatoid arthritis that developed neuritis optica after the fourth dose of infliximab and had a good outcome after anti-TNF withdrawal, associated with glucocorticoid treatment. In addition, the previous cases of ON induced by anti-TNF agents were reviewed.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22198693     DOI： 10.1007/s00296-011-2316-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  21 in total

Review 1.  Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

Authors:  W H Robinson; M C Genovese; L W Moreland
Journal:  Arthritis Rheum       Date:  2001-09

2.  Retrobulbar optic neuritis associated with infliximab.

Authors:  Rod Foroozan; Lawrence M Buono; Robert C Sergott; Peter J Savino
Journal:  Arch Ophthalmol       Date:  2002-07

3.  Infliximab-associated retrobulbar optic neuritis.

Authors:  Luis J Mejico
Journal:  Arch Ophthalmol       Date:  2004-05

4.  [Retrobulbar optic neuritis during infliximab treatment for ulcerative colitis].

Authors:  R Hejazi; J-F Colombel; L Peyrin-Biroulet
Journal:  Gastroenterol Clin Biol       Date:  2008-03-04

5.  Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy.

Authors:  In-Sook J Shin; Alan N Baer; Hyon J Kwon; Elektra J Papadopoulos; Jeffrey N Siegel
Journal:  Arthritis Rheum       Date:  2006-05

6.  [Retrobulbar optic neuritis associated with Infliximab].

Authors:  A Bidaguren; A Müller-Thyssen; A Blanco; J Mendicute; M Ubeda
Journal:  Arch Soc Esp Oftalmol       Date:  2007-02

7.  [Optic neuritis associated with infliximab].

Authors:  T H C Tran; D Milea; N Cassoux; B Bodaghi; P Bourgeois; P LeHoang
Journal:  J Fr Ophtalmol       Date:  2005-02       Impact factor: 0.818

8.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

9.  Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.

Authors:  Carlton W Thomas; Brian G Weinshenker; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2004-01       Impact factor: 5.325

Review 10.  Infliximab and anterior optic neuropathy: case report and review of the literature.

Authors:  Jane W Chan; Alberto Castellanos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-11-15       Impact factor: 3.117
View more
  6 in total

1.  Optic Neuritis Associated or Not with TNF Antagonists in Patients with Inflammatory Bowel Disease.

Authors:  Benjamin Alexandre; Yves Vandermeeren; Olivier Dewit; Tom Moreels; Nanne de Boer; Anjan Dhar; Chris Ziady; Ariella Bar-Gil Shitrit; Flavio Steinwurz; Njegica Jojic; Giuseppe Costantino; Benoit Bihin; Jean-François Rahier; Konstantinos H Katsanos
Journal:  J Crohns Colitis       Date:  2016-01-12       Impact factor: 9.071

Review 2.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 3.  Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping.

Authors:  Ippazio Cosimo Antonazzo; Emanuel Raschi; Luca Vignatelli; Elisa Baldin; Trond Riise; Roberto D'Alessandro; Fabrizio De Ponti; Elisabetta Poluzzi
Journal:  Drug Saf       Date:  2017-09       Impact factor: 5.606

Review 4.  CNS Demyelination with TNF-α Blockers.

Authors:  Elissavet Kemanetzoglou; Elisabeth Andreadou
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

5.  Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.

Authors:  E Andreadou; E Kemanetzoglou; Ch Brokalaki; M E Evangelopoulos; C Kilidireas; A Rombos; E Stamboulis
Journal:  Case Rep Neurol Med       Date:  2013-05-16

6.  Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.

Authors:  Evripidis Kaltsonoudis; Anastasia K Zikou; Paraskevi V Voulgari; Spyridon Konitsiotis; Maria I Argyropoulou; Alexandros A Drosos
Journal:  Arthritis Res Ther       Date:  2014-06-17       Impact factor: 5.156
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.